Indian stocks: Visit www.stage2stocks.com →

Quantum Biopharma Ltd. Class B

Stage 4 · Declining · week 11→4 today

As of Oct 22, 2026, Quantum Biopharma is in Stage 4, the downtrend phase, now in its first week (since Oct 22, 2026). It closed at $2.27, 84.3% below its 52-week high and below its 200-day average, which is falling.

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. More about the company

$2.27
+5.36% today
$14.6M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is QNTM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 55w
S2 16w
S4 24w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 8w → S1 1w → S4 55w → S1 7w → S4 7w → S1 6w → S2 5w → S3 2w → S2 16w → S3 10w → S4 24w → S1 9w → S4 11w → S1 3w → S4 1w current
Total tracked: 166 weeks across 15 stage runs.

QNTM among Biotechnology493rd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…493QNTMStage 4 · wk 19−41.5%
vs 52W High
-84.3%
$2.10 lo$14.44 hi
84.3% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 1
1w13w26w
Week 1, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-43.6%
200 DMA: $4.03 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.76x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-41.5%
3M
-24.1%
6M
-29.3%
YTD
-67.6%
1Y
-84.5%
Scan Membership
Breakout Watch
Latest: 2025-05-16
4 appearances in last 60 days. First seen: 2023-02-08.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S41→4
Wk 1 · Vol 0.76x
2026-10-21S1
Wk 4 · Vol 0.43x
2026-10-20S1
Wk 3 · Vol 0.21x
2026-10-19S1
Wk 3 · Vol 0.26x
2026-10-16S1
Wk 3 · Vol 0.79x
2026-10-15S1
Wk 3 · Vol 0.44x
2026-10-14S1
Wk 3 · Vol 0.74x
2026-10-13S1
Wk 2 · Vol 0.34x
2026-10-12S1
Wk 2 · Vol 0.66x
2026-10-09S1
Wk 2 · Vol 0.54x
2026-10-08S1
Wk 2 · Vol 0.32x
2026-10-07S1
Wk 2 · Vol 0.63x
Moving averages & range
50 DMA
$3.25
200 DMA
$4.03
52W High
$14.44
52W Low
$2.10
5D Low
$2.15
Resistance levels (recent highs)
20d High
$3.96
60d High
$4.00
120d High
$9.24
250d High
$13.90
Next resistance
+74.4%
to 20d High
ROE
-621.5%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 2.2

Quantum Biopharma: quick answers

What stage is Quantum Biopharma in?

As of Oct 22, 2026, Quantum Biopharma (QNTM) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Quantum Biopharma in an uptrend?

No. Quantum Biopharma is in a Stage 4 downtrend. It trades 43.6% below its 200-day average, which is falling.

How far is Quantum Biopharma from its 52-week high?

Quantum Biopharma closed at $2.27 on Oct 22, 2026, 84.3% below its 52-week high of $14.44. Its 52-week low is $2.10.

How has Quantum Biopharma performed over the past year?

As of Oct 22, 2026, Quantum Biopharma is down 84.5% over the past year and down 67.6% so far in 2026.

Which sector and industry is Quantum Biopharma in?

Quantum Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.